Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
-
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
-
Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates
-
Monte Rosa Therapeutics Announces First Subjects Dosed in P1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader
-
Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines
-
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inf
-
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
-
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
-
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025
-
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results